EUVIMEDEUVIMED entdecken
Open Access

Neonatal Outcomes Following Selective Serotonin Reuptake Inhibitor Use During Pregnancy

Layla Aref, Jacob J Hughey, Sherwin Shirazi, Jennifer M S Sucre, Lisa Bastarache

JAMA Network Open · 13.07.2026 · 9 (7) · e2622790

DOI: 10.1001/jamanetworkopen.2026.22790 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 13.07.2026. Verfasst von Layla Aref und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee. Hauptthemen laut MEDLINE: Selective Serotonin Reuptake Inhibitors, Pregnancy Outcome, Pregnancy Complications. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Evaluating the safety of selective serotonin reuptake inhibitors (SSRIs) during pregnancy is challenging due to ethical barriers to randomized trials and potential confounding in observational studies.

Objective

To compare neonatal outcomes for pregnancies with SSRI continuation vs those with SSRI discontinuation using a target trial framework. Design, Setting, and Participants This cohort study comprised target trials using electronic health records of linked mothers and neonates from a single academic center. The periconception trial examined congenital anomalies with first-trimester exposure, and the early-pregnancy trial evaluated nonanomaly outcomes with first- or second-trimester exposure. Participants were women with singleton pregnancies (2006 to 2022) with SSRI use within the 2 years before conception and at least 1 prenatal visit during the first trimester (periconception trial) or during the first or second trimester (early-pregnancy trial). Data were analyzed from May 2022 to December 2023. Exposure SSRI continuation vs discontinuation during pregnancy. Main Outcomes and Measures Apgar scores, meconium in amniotic fluid, neonatal intensive care unit (NICU) admission, preterm birth, birth weight, respiratory distress, feeding problems, hypoglycemia, hypothermia, pulmonary hypertension, cesarean delivery, and congenital anomalies.

Results

The early-pregnancy trial included 1014 pregnancies (mean [SD] maternal age, 30.3 [5.4] years). The periconception trial included 807 pregnancies (mean [SD] maternal age, 30.4 [5.5] years). SSRI continuation was associated with lower Apgar scores at 1 minute (mean difference [MD], –0.39; 95% CI, –0.60 to –0.18) and 5 minutes (MD, –0.28; 95% CI, –0.42 to –0.13), and increased risk of meconium in amniotic fluid (odds ratio [OR], 1.73; 95% CI, 1.22 to 2.45). No significant associations were found for congenital anomalies (OR, 1.09; 95% CI, 0.63 to 1.90), though this result should be interpreted with caution given limited sample size. No differences were found for neonatal intensive care unit admission (OR, 1.23; 95% CI, 0.82 to 1.83) or other outcomes. Conclusions and Relevance In this cohort study, SSRI continuation during pregnancy was associated with impaired neonatal adaptation but not with severe complications or NICU admission. These findings highlight the importance of appropriate comparator selection to minimize confounding and illustrate how target trial emulation can improve causal inference in studies of medication safety during pregnancy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Selective Serotonin Reuptake InhibitorsPregnancy OutcomePregnancy ComplicationsHumansFemalePregnancyInfant, NewbornAdultApgar ScoreCohort StudiesPremature Birth

Substanzen

Selective Serotonin Reuptake Inhibitors

Autor:innen und Institutionen

  • Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Biodevelopmental Origins of Lung Disease (BOLD) Center, Vanderbilt University School of Medicine, Nashville, Tennessee.
  • Department of Cell and Developmental Biology, Vanderbilt University, Nashville, Tennessee.

Förderung

  • NICHD NIH HHS

Zitieren

APA

Aref, L., Hughey, J. J., Shirazi, S., Sucre, J. M. S., & Bastarache, L. (2026). Neonatal Outcomes Following Selective Serotonin Reuptake Inhibitor Use During Pregnancy. JAMA Network Open, 9(7), e2622790. https://doi.org/10.1001/jamanetworkopen.2026.22790

Vancouver

Aref L, Hughey JJ, Shirazi S, Sucre JMS, Bastarache L. Neonatal Outcomes Following Selective Serotonin Reuptake Inhibitor Use During Pregnancy. JAMA Network Open. 2026;9(7):e2622790. doi:10.1001/jamanetworkopen.2026.22790

BibTeX
@article{Aref2026,
  author = {Aref, Layla and Hughey, Jacob J and Shirazi, Sherwin and Sucre, Jennifer M S and Bastarache, Lisa},
  title = {Neonatal Outcomes Following Selective Serotonin Reuptake Inhibitor Use During Pregnancy},
  journal = {JAMA Network Open},
  year = {2026},
  volume = {9},
  number = {7},
  pages = {e2622790},
  doi = {10.1001/jamanetworkopen.2026.22790}
}
Kostenlos starten →